{"id":41096,"date":"2025-09-10T16:33:19","date_gmt":"2025-09-10T08:33:19","guid":{"rendered":"https:\/\/flcube.com\/?p=41096"},"modified":"2025-09-10T16:33:20","modified_gmt":"2025-09-10T08:33:20","slug":"corxel-and-wuxi-forge-cardiovascular-partnership-to-accelerate-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41096","title":{"rendered":"Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development"},"content":{"rendered":"\n

China\u2011based Corxel Pharmaceuticals (CORXEL)<\/strong> and WuXi STA, a subsidiary of WuXi AppTec<\/strong> \u00a0(SHA: 603259<\/a>), have announced a strategic collaboration to develop, manufacture, and globally supply drug products for Corxel\u2019s cardiovascular and metabolic pipeline. The alliance focuses on drug\u2011product development for Corxel\u2019s core portfolio and on delivering clinical\u2011trial materials and future commercial products worldwide.<\/p>\n\n\n\n

Core Pipeline Highlights<\/h2>\n\n\n\n
Asset<\/th>Indication<\/th>Key Features<\/th><\/tr><\/thead>
CX11<\/strong><\/td>Obesity \/ overweight<\/td>Oral GLP\u20111 receptor agonist with proven weight\u2011loss efficacy<\/td><\/tr>
JX10<\/strong><\/td>Acute ischemic stroke (AIS)<\/td>Novel thrombolytic with dual anti\u2011inflammatory activity<\/td><\/tr>
JX09<\/strong><\/td>Hypertension<\/td>Highly selective aldosterone synthase inhibitor (ASI)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

These small\u2011molecule candidates target high\u2011burden cardiovascular and metabolic diseases, positioning Corxel for a rapid clinical\u2011pipeline progression.<\/p>\n\n\n\n

Why WuXi STA?<\/h2>\n\n\n\n